Two-Phase Study Leads to Monteloeder's Newest Nootropic for Cognitive Performance

Mindrevive™, composed of extracts of sage and Japanese pagoda tree, found to help enhance mental resilience in older adults

MADRID, Feb. 25, 2025 /PRNewswire/ -- A new study illustrates the research journey behind the creation of Monteloeder's latest nootropic formulation Mindrevive™. The study spans the process from laboratory analysis of various botanical candidates to assess and compare their cognitive potential, to a clinical trial of the final selected composition. Sage extract (Salvia officinalis) together with Japanese pagoda tree (Sophora japonica) emerged as the combination with the highest cognitive support potential demonstrating significant improvements in memory, learning and execution in a clinical trial.

The results of this two-in-one study led nutraceutical leader Monteloeder, a subsidiary of SUANNUTRA to create its proprietary "smart supplement" Mindrevive™, designed to help preserve cognitive vitality specifically in adults aged 50 and older who are going through typical age-related changes. Serving the healthy ageing category, the composition targets memory, mental clarity and focus.

Specifically, the compounds in Mindrevive™ were found to help:

• Reduce oxidative stress
• Increase neuronal survival and regeneration
• Activate antioxidant defenses
• Enhance memory and learning
• Support growth factor release (NGF, BDNF, VEGF)
• Maintain cognitive health

Study Details

The two-phase study ushered in a research-driven approach to formulation. Led by Pau Navarro, PhD, published December 2024 in Applied Sciences first involved in vitro analysis of nine unique botanical compounds that were assessed for their nootropic properties. These included water-ethanol extracts of bilberry, blueberry, bacopa (Bacopa monnieri), sage, saffron, rhodiola (Rhodiola rosea), ginkgo biloba, panax ginseng roots, and gotu kola, and, Japanese pagoda tree. These herb extracts were tested in human neural stem cell cultures exposed to oxidative stress. The researchers analyzed each botanical's ability to suppress harmful reactive oxygen and reactive nitrogen species (ROS and RNS), to promote cell survival, and to stimulate neural cell growth factors.

Results of this first phase demonstrated that sage standardized in rosmarinic acid exhibited the most noticeable effects on reducing oxidative stress and cell death, while stimulating brain-derived neurotrophic factor (BDNF, a protein involved in in improving brain cell growth and vital for long-term memory and cognitive function). Nerve growth factor (NGF) levels were also increased, a protein associated with neuronal function and maintenance. Additionally, the production of vascular endothelial growth factor (VEGF) was significantly enhanced. VEGF plays a role in supporting healthy circulation, which contributes to oxygen and nutrient delivery to brain cells.

When joined with sophora extract enriched to 95% rutin, the BDNF effect was significantly augmented. Rutin is recognized as a powerful antioxidant and helps reduce age-related neuronal degeneration. Moreover AChE (acetylcholinesterase) activity was reduced by more than 60%. High AChE activity is known to impair nerve signaling through the breakdown of acetylcholine, a neurotransmitter crucial for learning, memory, and muscle function.

New light shed on Sage's cognitive wellness properties

"The nine botanicals selected for analysis are widely recognized for their antioxidant properties and role in supporting cognitive function, with extensive documentation in scientific research," informs Jonathan Jones, Chief Scientific Officer, at Monteloeder. "Some of these ingredients have been evaluated in clinical studies exploring cognitive health. Sage, in particular, has often been overlooked in discussions about cognitive support, yet it stood out in our screening trials. In fact, sage was the only extract to increase the expression of all analyzed factors associated with neuronal function and antioxidant defenses. When combined with rutin, we observed significant enhancements in the production of BDNF, a key molecule involved in brain signaling and cognitive processes. Specifically, it is the major growth factor implicated in memory processes and learning. Research suggests that maintaining optimal BDNF levels is important for overall brain health."

Phase Two

A subsequent randomized, double-blind placebo-controlled clinical study tested the effects of the chosen composition Mindrevive™ on 121 healthy volunteers aged 50–65 years and suffering from mild cognitive impairment. Assigned to three groups, the participants were given 250mg Mindrevive™, 400mg Mindrevive™, or a placebo every morning after breakfast over a period of 3 months.

At six weeks and again at 12 weeks, the participants were assessed through two questionnaires: the MoCA (Montreal Cognitive Assessment), a validated to assess cognitive function, and the ADAS-Cog (Alzheimer's Disease Assessment Scale-Cognitive Subscale), used to evaluate key cognitive parameters such as memory, language, attention, and problem-solving.

From Week 6, the 250mg Mindrevive™ dose was shown to contribute to improving short-term memory recall, while the 400mg contributed to improving both short-term memory recall and abstract reasoning after 12 weeks of intake and consistently outperformed the placebo group.

The ADAS-Cog test demonstrated significant cognitive improvements with both of the Mindrevive™ doses compared to placebo after 12 weeks. Intragroup analysis showed more pronounced and rapid enhancements with the higher dose. Notably, the supplementation positively impacted language skills at Week 12 and motor skills as soon as Week 6. Individual item analysis revealed improvements in word recall, word recognition, and command performance across both doses.

Cognitive health is a growing concern among adults 65 and older, with conditions affecting memory and mental performance ranking among the Top 10 chronic issues, according to the National Council on Aging., recent reports by Future Markets Insights, Inc. forecast cognitive health supplement sales to "experience significant growth," reaching nearly USD17 billion by 2033 at a CAGR of 13.3%. Within this, the market research group predicts the nootropic supplement market to double from USD2.2 billion to USD4.2 billion in that time, at a CAGR of 9.0%.

"Cognitive function naturally changes with age" explains Mariana Ortega, Science Marketing Manager of SUANNUTRA. "Mindrevive™ is formulated with clinically studied ingredients to help maintain cognitive performance and support brain health. This is especially relevant for older adults who are proactively looking for natural solutions to preserve mental sharpness and overall well-being."

About Monteloeder

Monteloeder contributes cutting-edge innovation and scientific rigor to the development of botanical health ingredients, featuring proprietary patented products supported by clinical studies. The company's portfolio has garnered international accolades in wellness, women health, and beauty from within. Monteloeder is a subsidiary of SUANNUTRA, which boasts a rich heritage of more than 125 years of combined experience in the European, US, and Asian nutraceutical sector.

Press Contact
NutriPR
Liat Simha
Tel: +972-9-9742893
E-mail: [email protected]
Twitter: @NutriPR
Website: www.nutripr.com

Company contact
Monteloeder, S.L., a subsidiary of SuanNutra
Mariana Ortega
Science Marketing Manager
E-mail: [email protected]
Website: www.suannutra.com

Photo: https://mma.prnewswire.com/media/2627204/MONTELOEDER_Two_Phase_Study.jpg

View original content to download multimedia:https://www.prnewswire.com/news-releases/two-phase-study-leads-to-monteloeders-newest-nootropic-for-cognitive-performance-302384620.html

SOURCE Monteloeder, S.L.